AstraZeneca Pharma India Limited and Dr. Reddy’s Laboratories Ltd. Collaborate to marketing for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and marketed in the Indian market.
Diabetes is a disease of epidemic scale in India with over 65 million affected people. Onglyza or saxagliptin AstraZeneca’s patented therapy, is an oral hypoglycemic which is an anti-diabetic therapy in the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.
Dr. Reddy’s Laboratories will be distributing Riax and Riax M in India. This partnership strengthens the company’s diabetes franchise in India. It enables AstraZeneca to expand usage of this molecule through wider reach to physicians and benefiting more number of diabetic patients.
Subscribe to PharmaTutor News Alerts by Email >>
